Busca avançada
Ano de início
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Modulation of Macrophage Responses by CMX, a Fusion Protein Composed of Ag85c, MPT51, and HspX from Mycobacterium tuberculosis

Texto completo
da Costa, Adeliane C. ; de Resende, Danilo P. ; Santos, Bruno de P. O. ; Zoccal, Karina F. ; Faccioli, Lucia H. ; Kipnis, Andre ; Junqueira-Kipnis, Ana P.
Número total de Autores: 7
Tipo de documento: Artigo Científico
Citações Web of Science: 3

Mycobacterium bovis Bacillus Calmette-Guerin (BCG) is a vaccine used to prevent tuberculosis (TB). Due to the poor protection conferred by BCG in adults, new, more effective formulations have been developed. A recombinant BCG vaccine expressing the CMX fusion protein Ag85c\_MPT51\_HspX (rBCG-CMX) induced Th1 and Th17 responses and provided better protection than BCG. It has been shown that Mycobacterium smegmatis expressing CMX also induces better protection than BCG and is a strong macrophage activator. The aim of the present study was to evaluate macrophage activation by the recombinant CMX fusion protein and by rBCG-CMX and to evaluate their ability to generate vaccine-specific immune responses. The results demonstrate that rCMX protein expressed by BCG (rBCG-CMX) activates pulmonary macrophages; increases the expression of activation molecules, cytokines, and MHC-II. The interaction with rCMX activates the transcription factor NF-kappa B and induces the production of the cytokines TGF-beta, TNF-alpha, and IL-6. The in vitro stimulation of bone marrow-derived macrophages (BMMs) from TLR-4 or TLR-2 KO mice showed that in the absence of TLR-4, IL-6 was not produced. rBCG-CMX was unable to induce CMX-specific Th1 and Th17 cells in TLR-4 and TLR-2 KO mice, suggesting that these receptors participate in their induction. We concluded that both the rBCG-CMX vaccine and the rCMX protein can activate macrophages and favor the specific immune response necessary for this vaccine. (AU)

Processo FAPESP: 14/07125-6 - Novos aspectos funcionais dos eicosanóides
Beneficiário:Lúcia Helena Faccioli
Linha de fomento: Auxílio à Pesquisa - Temático